



Prior Authorization Approval Criteria

Adcirca (tadalafil)

Generic name:	tadalafil
Brand name:	Adcirca
Medication class:	vasodilators; phosphodiesterase Type 5 inhibitors
FDA-approved uses:	Treatment of pulmonary arterial hypertension (WHO group I) to improve exercise ability.
Available dosage forms:	20mg Tablets
Usual dose:	40 mg once daily
Approximate monthly cost: (based on AWP 2009)	\$1094.40
Duration of therapy:	indefinite

Criteria for use (*bullet points below are all inclusive unless otherwise noted*):

- The indicated diagnosis (including any applicable labs and /or tests) and medication usage must be supported by documentation from the patient's medical records.
- Clinical diagnosis of pulmonary hypertension WHO group I.
- Patients with NYHA class II-IV.
- Must have tried and failed a calcium channel blocker if they have a positive vasoreactivity test.

Contraindication:

- Patients receiving organic nitrates in any form, either regularly or intermittently due to potentiation of the hypotensive effects of nitrates.
- Hypersensitivity reaction to Adcirca or Cialis.

Not approved if:

- Patient does not meet the above stated criteria.
- Patient has any contraindications to the use of Adcirca.

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 12/09/09